Status: Recruiting
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors:A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
Participants needed: 59
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eastern Hepatobiliary Surgery HospitalUpdated: Jul 10, 2025Locations: 1
Eligibility criteria
The patient voluntarily participates in the trial, provides full informed consen... [+16]
Cholangiocarcinoma of rare histopathological types confirmed by histology or cyt... [+14]